Pasithea net loss widens 41.9% to $5.27 million in Q2 2026

Reuters2026/08/14 20:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pasithea Therapeutics posted a Q2 net loss of $5.27 million, widening 41.9% from a year earlier.
Operating loss widened 49.9% to $5.71 million as research and development expense climbed 71.5% to $3.69 million.
General and administrative costs increased 22% to $2.03 million, while other income rose to $439,430.
For the first half, net loss widened 11.9% to $8.14 million as operating loss increased 41.4% to $10.59 million.
Cash, cash equivalents and restricted cash fell about $9.5 million in the first half; it had about $45.7 million on hand at June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090146), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pasithea net loss widens 41.9% to $5.27 million in Q2 2026

You may also like

Crypto prices